Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
source: pixabay.com

Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease

  According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…

Continue Reading Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
source: pixabay.com

Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward

As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…

Continue Reading Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
source: pixabay.com

Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease

  Parkinson’s News Today recently published an article containing new information about biomarkers in Alzheimer’s disease that can be linked to the early stages of Parkinson’s disease. Many people with…

Continue Reading Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Image by Markus Spiske from Pixabay

Scientists Can Identify Schwann Cells Using Novel Bar Code Technique

Scientists and researchers have long known how important glial cells are to the nervous system. Not only do these cells make up a majority of cells within the central nervous…

Continue Reading Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases
source: pixabay.com

Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases

Anavex Life Sciences Corporation has recently announced that they will conduct a clinical trial for their small molecule, ANAVEX®3-71. This therapy is intended to treat neurodegenerative and neurodevelopmental conditions, such…

Continue Reading Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases

Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier

It is acknowledged in the medical community that clumps of misfolded tau proteins and amyloid-β are markers of Alzheimer’s disease. The evidence presented in recent article in Nature, shows that…

Continue Reading Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier
Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults
source: pixabay.com

Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults

  According to MedPage Today, carriers of the gene variation APOE4 are much more at risk of developing Alzheimer's disease. However, researchers found that one copy of the Klotho gene mutation,…

Continue Reading Klotho Gene Variant Reduces Alzheimer’s Disease Risk in High-Risk Adults
Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification
source: pixabay.com

Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification

  In February 2020, Epigenetics published results of a study reporting that researchers have found an early sign of Alzheimer’s disease in DNA modification (methylation) that had been overlooked. Patients…

Continue Reading Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification
Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases
source: pixabay.com

Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases

  For years scientists have tried to understand how and why tau, well known to researchers for its implication in Alzheimer’s disease, changes from its normal form to a harmful…

Continue Reading Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases
Biogen to Relaunch its Alzheimer’s Drug with FDA Clearance in New Study
source: pixabay.com

Biogen to Relaunch its Alzheimer’s Drug with FDA Clearance in New Study

  According to an article in the Alzheimer’s publication Being Patient, participants who had been enrolled in the discontinued phase three trials of aducanumab will start receiving the drug as…

Continue Reading Biogen to Relaunch its Alzheimer’s Drug with FDA Clearance in New Study
ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
source: pixabay.com

ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention

  Janssen R&D, a division of Johnson & Johnson (J&J), has partnered with the UK Biobank and others according to a recent news release by 3BL Media. It is noteworthy…

Continue Reading ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention

After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?

  Over the years Alzheimer’s patients and their families have seen more than one hundred twenty drugs that were developed for the treatment of Alzheimer's have failed. For a while,…

Continue Reading After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?

ALZHEIMER’S:  Scientists are Back to Square One; Will Bryostatin-1 be the Missing Link?

  Pharmaceutical companies have spent billions of dollars on Alzheimer’s research. The target has been the toxic protein, amyloid-beta. According to a recent article in NPR News, this theory was…

Continue Reading ALZHEIMER’S:  Scientists are Back to Square One; Will Bryostatin-1 be the Missing Link?

Scientists are Ramping Up Their Attack on Alzheimer’s Disease Through Immunotherapy

In the early 1900s, German psychiatrist Alois Alzheimer, while studying about the decline in brain function, recognized a correlation between behavioral changes and the buildup of tangles and plaques in…

Continue Reading Scientists are Ramping Up Their Attack on Alzheimer’s Disease Through Immunotherapy